golfyeti - Probably best to have BDAZ chime in on this but I'll give it a go. Once we are able to have sales (FDA/EMA approval) for the primary use "any" patient within any of the parameters of diabetic cardio issues could be prescribed ABL. In a nutshell many more potential patients could be prescribed ABL than if there were no secondary indications in the study.

Anyone else that can explain this better please do.

tada